Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD)
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Guanfacine extended-release (GXR) is a non-stimulant approved in the US for treatment of attention deficit/hyperactivity disorder (ADHD). GXR is a 'first in class' α(2A)-adrenoceptor agonist reformulated to optimize efficacy. GXR enters a rapidly growing but crowded ADHD market as an alternative not only to psychostimulants but also to atomoxetine. AREAS COVERED IN THIS REVIEW: Pharmacodynamics, pharmacokinetics, clinical efficacy and safety of GXR are covered based on a literature review (MEDLINE and EMBASE) from 1980 to 2010. Two large pivotal controlled trials are reviewed along with companion safety studies over 24 months. Collateral studies in ADHD children with oppositional symptoms and combination use of GXR in psychostimulant partial-responders are featured. WHAT THE READER WILL GAIN: Novel aspects of apparent GXR mechanism of action may complement existing treatments. Study evidence indicates that GXR is a well-tolerated and effective treatment for children and adolescents with ADHD, and appears efficacious to reduce oppositional symptoms in children with these complicating features. The GXR safety database reflects mild and asymptomatic decreases in both blood pressure and heart rate throughout, with most adverse events being somnolence-related and time-limited. TAKE HOME MESSAGE: This review of GXR will allow the reader to determine the place for GXR in the ADHD treatment landscape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes
Castellanos, F. X., & Tannock, R. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn896 · Cited by 1,827 · cited 1×
“Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous, multifactorial disorder that can involve aspects of temperament (impulsivity), motivation (reward), behavior (hyperactivity), and cognition (inattention, working memory) [1-3].”
BackgroundPliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Psychological heterogeneity in AD/HD—a dual pathway model of behaviour and cognition
Sonuga-Barke, E. J. S. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00432-6 · Cited by 901
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Nigg, J. T. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.011 · Cited by 513 · cited 1×
“Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous, multifactorial disorder that can involve aspects of temperament (impulsivity), motivation (reward), behavior (hyperactivity), and cognition (inattention, working memory) [1-3].”
BackgroundPLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Sallee, F. R., Mcgough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318191769e · Cited by 391
Self-citationArnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · cited 1×
“GXR is a selective a2A-receptor agonist thought to directly engage postsynaptic receptors in the PFC, an area of the brain believed to play a major role in attentional and organizational functions that preclinical research has linked to ADHD [21,22].”
BackgroundBiederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317
Cited by
Cortese, S., Holtmann, M., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Graham, J., Taylor, E., Sergeant, J., et al. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12036 · Cited by 336
“(Sallee & Eaton, 2010).”
BackgroundInfluentialDittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Bloomfield, R., Caballero, B., Higgins, N., Hodgkins, P., Lyne, A., Civil, R., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0104-8 · Cited by 88
Noradrenergic control of the bed nucleus of the stria terminalis in stress and reward
Flavin, S. A., & Winder, D. G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.013 · Cited by 62
Fredriksson, I., Jayaram-Lindström, N., Wirf, M., Nylander, E., Nyström, E., Jardemark, K., & Steensland, P. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.294 · Cited by 35
“Guanfacine, an a-2-adrenoreceptor agonist, was recently FDA approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents (Sallee et al, 2009a,b; Sallee and Eaton, 2010).”
BackgroundResultInfluentialSchulz, K. P., Clerkin, S. M., Fan, J., Halperin, J. M., & Newcorn, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2893-8 · Cited by 35
Metadata
- Authors
- Sallee, F. R., & Eaton, K.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2010-09-10
- Volume
- 11
- Issue
- 15
- Pages
- 2549-2556
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2112229136
- Cited by
- 20
- References
- 25
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD). https://app.cochat.ai/papers/10.1517/14656566.2010.517523
- The paper
- Sallee, F. R., & Eaton, K. (2010). Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD). Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2010.517523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.